Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis

Pioglitazone treatment improves insulin resistance (IR), glucose metabolism, hepatic steatosis, and necroinflammation in patients with nonalcoholic steatohepatitis (NASH). Because abnormal lipid metabolism/elevated plasma free fatty acids (FFAs) are important to the pathophysiology of NASH, we examined the impact of pioglitazone therapy on adipose tissue insulin resistance (Adipo‐IR) during the treatment of patients with NASH. To this end, we assessed glucose/lipid metabolism in 47 patients with impaired glucose tolerance/type 2 diabetes mellitus and NASH and 20 nondiabetic controls. All individuals underwent a 75‐g oral glucose tolerance test (OGTT) in which we measured glucose tolerance, IR, and suppression of plasma FFAs. We also measured Adipo‐IR index (fasting, FFAs × insulin), hepatic fat by magnetic resonance spectroscopy, and liver histology (liver biopsy). Patients were randomized (double‐blind) to diet plus pioglitazone (45 mg/day) or placebo for 6 months, and all measurements were repeated. We found that patients with NASH had severe Adipo‐IR and low adiponectin levels. Fasting FFAs were increased and their suppression during the OGTT was impaired. Adipo‐IR was strongly associated with hepatic fat (r= 0.54) and reduced glucose clearance both fasting (r=0.34) and during the OGTT (r=0.40, all P <0.002). Pioglitazone significantly improved glucose tolerance and glucose clearance, steatosis and necroinflammation (all P<0.01‐0.001 versus placebo). Fasting/postprandial plasma FFAs decreased to levels of controls with pioglitazone (P<0.02 versus placebo). Adipo‐IR decreased by 47% and correlated with the reduction of hepatic fat (r=0.46, P=0.009) and with the reduction in hepatic necroinflammation (r=0.47, P=0.0007). Conclusion: Patients with NASH have severe Adipo‐IR independent of the degree of obesity. Amelioration of Adipo‐IR by pioglitazone is closely related to histological improvement and plays an important role during treatment of patients with NASH. (HEPATOLOGY 2009)

[1]  G. Aithal,et al.  Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. , 2008, Gastroenterology.

[2]  J. Horton,et al.  Molecular mediators of hepatic steatosis and liver injury. , 2004, The Journal of clinical investigation.

[3]  R. DeFronzo,et al.  Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. , 2004, American journal of physiology. Endocrinology and metabolism.

[4]  G. Marchesini,et al.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.

[5]  P. Scherer,et al.  Adiponectin: a relevant player in PPARγ-agonist-mediated improvements in hepatic insulin sensitivity? , 2005, International Journal of Obesity.

[6]  G. Bray,et al.  Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. , 2005, Diabetes.

[7]  A. Sanyal,et al.  Recent advances in nonalcoholic fatty liver disease , 2009, Current opinion in gastroenterology.

[8]  J. Clore,et al.  Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.

[9]  E. Ferrannini,et al.  Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms , 2005, Diabetologia.

[10]  R. DeFronzo,et al.  A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. , 2003, Diabetes.

[11]  L. J. Hardies,et al.  Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. , 2004, The Journal of clinical endocrinology and metabolism.

[12]  A. Sanyal,et al.  Recent advances in nonalcholic fatty liver disease , 2008, Current opinion in gastroenterology.

[13]  P. Libby,et al.  Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. , 2007, The American journal of cardiology.

[14]  L. Groop,et al.  Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. , 1989, The Journal of clinical investigation.

[15]  Y. Miyazaki,et al.  The Effect of Pioglitazone on the Liver , 2006, Diabetes Care.

[16]  Michael Roden,et al.  Mechanisms of Disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[17]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[18]  B. S. Mohammed,et al.  Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. , 2008, Gastroenterology.

[19]  D. Pessayre,et al.  Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. , 2006, Mitochondrion.

[20]  J. Clore,et al.  A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  A. Diehl.  Lessons from animal models of NASH. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

[22]  S. Uchida,et al.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.

[23]  A. Häkkinen,et al.  Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. , 2002, The Journal of clinical endocrinology and metabolism.

[24]  B. Spiegelman.  PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[25]  K. Cusi,et al.  Chronic low-dose lipid infusion in healthy patients induces markers of endothelial activation independent of its metabolic effects. , 2008, Journal of the cardiometabolic syndrome.

[26]  S. Lemieux,et al.  Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. , 2001, Diabetes.

[27]  S. Caldwell,et al.  Therapy of NAFLD: insulin sensitizing agents. , 2006, Journal of clinical gastroenterology.

[28]  K. Cusi.  The Epidemic of Type 2 Diabetes Mellitus: Its Links to Obesity, Insulin Resistance, and Lipotoxicity , 2009 .

[29]  M. Jimenez-Linan,et al.  Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. , 1997, The Journal of clinical investigation.

[30]  J. Hoofnagle,et al.  A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis , 2004, Hepatology.

[31]  K. Cusi,et al.  Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. , 2007, American journal of physiology. Endocrinology and metabolism.

[32]  R. DeFronzo,et al.  Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. , 2004, The Journal of clinical endocrinology and metabolism.

[33]  Amalia Gastaldelli,et al.  Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. , 2007, Gastroenterology.

[34]  S. Cotler,et al.  Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. , 2008, World journal of gastroenterology.

[35]  Philippe Giral,et al.  Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. , 2008, Gastroenterology.

[36]  E. Parks,et al.  Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states. , 2006, The Journal of clinical endocrinology and metabolism.

[37]  L. Krugner-Higby,et al.  Mitochondria in nonalcoholic fatty liver disease. , 2004, Clinics in liver disease.

[38]  J. Olefsky.  Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists , 2000 .

[39]  M. Matsuda,et al.  Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients , 2001, Diabetologia.

[40]  R. Unger.  Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications , 1995, Diabetes.

[41]  G. Bray,et al.  The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. , 2004, Diabetes care.

[42]  A. Häkkinen,et al.  Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. , 2004, Diabetes.

[43]  P. Scifo,et al.  Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver , 2007, Hepatology.

[44]  M. Lazar,et al.  A Dominant-negative Peroxisome Proliferator-activated Receptor γ (PPARγ) Mutant Is a Constitutive Repressor and Inhibits PPARγ-mediated Adipogenesis* , 2000, The Journal of Biological Chemistry.

[45]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[46]  P. Libby,et al.  Inflammation in Diabetes Mellitus: Role of Peroxisome Proliferator-Activated Receptor–α and Peroxisome Proliferator-Activated Receptor–γ Agonists , 2007 .

[47]  K. Cusi,et al.  New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD) , 2009, Annals of medicine.

[48]  B. Neuschwander‐Tetri,et al.  Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐γ ligand rosiglitazone , 2003, Hepatology.

[49]  M. Lazar,et al.  A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. , 2000, The Journal of biological chemistry.

[50]  Thiazolidinediones in NASH. An odd couple meant to be? , 2009, Journal of clinical gastroenterology.

[51]  K. Kowdley,et al.  Nonalcoholic steatohepatitis: a twenty-first century epidemic? , 2006, Journal of Clinical Gastroenterology.

[52]  T. Takamura,et al.  Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPARgamma mRNA expression in 3T3-L1 adipocytes. , 2001, European journal of pharmacology.